Literature DB >> 14690692

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.

Sharyn D Baker1, Ming Zhao, Ping He, Michael A Carducci, Jaap Verweij, Alex Sparreboom.   

Abstract

An analytical procedure for the simultaneous determination of the anticancer agent docetaxel (Taxotere) and its formulation vehicle polysorbate 80 (Tween 80) in human plasma samples is described. Sample pretreatment involved a double liquid-liquid extraction step with a mixture of acetonitrile/n-butyl chloride (1/4, v/v). Separation of the compounds of interest, including the internal standard paclitaxel, was achieved on a reversed-phase Waters X-Terra mass spectrometry (MS) column (50 x 2.1mm internal diameter) packed with a 3.5-microm octadecyl stationary phase, using isocratic elution. Detection of docetaxel and polysorbate 80 was performed using tandem MS detection with electrospray ionization. Validation results indicated that the method is accurate and precise and has lower limits of quantitation of 0.500 nM (approximately 0.4 ng/ml) and 1.00 microg/ml for docetaxel and polysorbate 80, respectively. The method was subsequently used to measure concentrations of docetaxel and polysorbate 80 in plasma samples in support of a project to assess the influence of polysorbate 80 concentrations on the disposition and toxicity profile of docetaxel in cancer patients receiving Taxotere.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14690692     DOI: 10.1016/j.ab.2003.09.038

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  17 in total

1.  Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.

Authors:  Jing Li; Julie Brahmer; Wells Messersmith; Manuel Hidalgo; Sharyn D Baker
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

Review 2.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

Authors:  Roisin M Connolly; Michelle A Rudek; Elizabeth Garrett-Mayer; Stacie C Jeter; Michele G Donehower; Laurie A Wright; Ming Zhao; John H Fetting; Leisha A Emens; Vered Stearns; Nancy E Davidson; Sharyn D Baker; Antonio C Wolff
Journal:  Breast Cancer Res Treat       Date:  2011-02-25       Impact factor: 4.872

4.  Evaporative light scattering detection based HPLC method for the determination of polysorbate 80 in therapeutic protein formulations.

Authors:  Vikram S Nayak; Zhijun Tan; Peter M Ihnat; Reb J Russell; Michael J Grace
Journal:  J Chromatogr Sci       Date:  2012-01       Impact factor: 1.618

5.  Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.

Authors:  Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-02       Impact factor: 3.333

6.  Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

Authors:  Dana Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  A Novel Docetaxel-Loaded Poly (ε-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment.

Authors:  Lin Mei; Yangqing Zhang; Yi Zheng; Ge Tian; Cunxian Song; Dongye Yang; Hongli Chen; Hongfan Sun; Yan Tian; Kexin Liu; Zhen Li; Laiqiang Huang
Journal:  Nanoscale Res Lett       Date:  2009-09-16       Impact factor: 4.703

8.  Enhancement of the solubility and efficacy of poorly water-soluble drugs by hydrophobically-modified polysaccharide derivatives.

Authors:  Widad Henni-Silhadi; Michel Deyme; Marie-Martine Boissonnade; Martine Appel; Didier Le Cerf; Luc Picton; Véronique Rosilio
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

9.  Pharmacogenetic pathway analysis of docetaxel elimination.

Authors:  S D Baker; J Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; R M Franke; S Hu; E G Schuetz; V Lamba; W A Messersmith; A C Wolff; M A Carducci; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2008-05-28       Impact factor: 6.875

10.  Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.

Authors:  Guangxi Zhai; Jun Wu; Guangya Xiang; Wenxue Mao; Bo Yu; Hong Li; Longzhu Piao; L James Lee; Robert J Lee
Journal:  J Nanosci Nanotechnol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.